Introduction
Since its discovery in 2013, the H7N9 influenza virus has been responsible for many epidemics in China. The infectious agent is dangerous because it may invade people and cause severe breathing issues, including mortality (Chen et al., 2022). The introduction will summarize the H7N9 influenza virus, covering its metabolic needs, structure, natural reservoir, cell type, history, morphology, and other essential characteristics. Orthomyxoviridae is a group of enveloped viruses, including the H7N9 influenza virus.
The exterior glycoproteins are hemagglutinin (H) and neuraminidase (N), utilized to categorize the virus and encoded by the virus’s fragmented RNA gene pool, which also contains instructions for 11 other amino acids (Mandary et al., 2019). Both the H7 and N9 subtypes of H7N9 influenza exist. Birds and vertebrates with the H7N9 influenza virus have respiratory tract infections. The pathogen has an 80–120 nm dimension and an elliptical or cylindrical shape.
The H7N9 influenza virus is an obligatory cytoplasmic organism, requiring a host body to reproduce. The pathogen uses the host cell’s metabolic system to reproduce its RNA sequence and generate protein chains. Untamed birds, especially ducks, are thought to be the H7N9 influenza virus’s primary host. Quail, ducks, and chickens are bird species susceptible to viral infection. H7N9 virus outbreaks in humans have mainly been brought on through contact with infected settings or live poultry (Guinat et al., 2023).
In 2013, a severe pneumonia outbreak in humans was recorded. This information led to the discovery of the H7N9 influenza strain in China. The microbe continued to propagate throughout China in surges, with the most significant severe cycle happening in 2017. Additionally, the illness was recently found in other nations, such as Cambodia, Laos, and Vietnam.
Diseases Caused by the Organism
Epidemiology and disease: The H7N9 influenza strain typically generates moderate to severe breathing disorders in people. Pneumonia, syndrome of acute respiratory distress, and even mortality are all possible outcomes of the infection. Although rare instances have been documented in other nations, China has seen the majority of H7N9 virus infections (Li et al., 2019). Many illnesses were brought on by contact with live chickens or infected settings.
The H7N9 influenza strain can cause coughing, fever, pneumonia, breathing difficulty, and a sore throat as symptoms and indications. Additionally, specific individuals may develop digestive problems like diarrhoea and vomiting. Septic shock, multiple organ failure, and acute breathing difficulties can result from severe H7N9 infections (Chen et al., 2020). H7N9 virus infection may negatively influence the ecosystem, especially in regions with significant levels of chicken farming.
The disease may propagate quickly in groups of chickens, causing numerous deaths and considerable monetary damage. Due to medication overuse in chicken farming to combat H7N9 and other infections, antibiotic-resistant microbes can emerge, which could severely affect human well-being and the ecosystem (Grzinic et al., 2023). Enhancing sanitation standards in poultry breeding, monitoring for infection in domestic and exotic birds, and raising public knowledge of the dangers of handling live chickens are all part of the H7N9 influenza virus control and preventive efforts (Rimi et al., 2019). There are also vaccinations for birds, though they could be more efficient. Human H7N9 infections can be treated with antiviral medications, but their efficacy depends on prompt detection and care.
Factors Employed by the Organism
The H7N9 influenza strain uses several elements to aid its development, reproduction, and pathogenicity. These elements are listed, described, and categorized in this paper according to their modes of operation. Mechanisms the organism uses include:
- The external glycoproteins hemagglutinin (HA) and neuraminidase (NA) are essential for the pathogenicity of the H7N9 influenza virus. While NA breaks down sialic acid from the outermost layer of cells with infection, enabling the pathogen to spread and propagate to other cells, HA facilitates the fixation of the pathogen to living membranes.
- RNA polymerase. The infectious agent makes infectious protein and copies its genetic material using its RNA polymerase, promoting the growth of new viruses and the propagation of disease.
- The H7N9 influenza virus prefers pulmonary tissue, enabling it to attack the lungs and produce respiratory disease effectively.
- The H7N9 influenza virus uses immune evasion to dodge host immune reactions. These techniques enable the infectious agent to avoid being recognized by human antigens.
- Antigenic drift and shift. The virus frequently experiences alterations in the HA and NA envelope glycoproteins, which enable it to evade the immune system and cause new infections.
- Reproduction in birds. The H7N9 influenza virus can reproduce in chickens, which enables the infection to remain in nature and can spread zoonotically to people.
Sorting factors of virulence according to their modes of attack:
- Antigenic drift and shift, which enable the organism to elude identification by human immune systems, are just two of the strategies used by the H7N9 influenza virus to avoid host immunological reactions. The infectious agent also makes proteins without structures that hinder interferon and other host defences against viruses.
- H7N9 viral infection can harm the respiratory system’s tissues and cells, resulting in acute respiratory distress syndrome and pneumonia. The pathogen accomplishes this by invading and multiplying in the respiratory tract’s cells, which damages tissues and causes cell death.
- The H7N9 influenza virus can multiply in pulmonary epithelium cells and disseminate to other cells via its NA glycoprotein, two strategies it employs to establish itself and increase inside the host. The viral infection can also spread to other people by escaping into respiratory fluids.
Treatment and Prevention
Antiviral drugs and vaccinations are the mainstays of prevention and treatment for H7N9 influenza virus outbreaks. Antiviral drugs are utilized to treat diseases caused by the H7N9 influenza virus and shorten the duration and extent of signs. Neuraminidase inhibitors (NAIs) and adamantanes are two antiviral drugs now accepted for managing influenza (Toots & Plumper, 2020).
NAIs are the recommended form of medication since specific H7N9 influenza virus variants have evolved to become resistant to adamantanes. The two NAIs that tend to be utilized for managing H7N9 influenza viral infections are oseltamivir and zanamivir. These medications prevent the influenza neuraminidase glycoprotein, which is necessary for the infectious agent to propagate from contaminated to undamaged tissues, from becoming active.
NAIs stop the virus from spreading and lessen the length and severity of manifestations by obstructing the metabolic processes of neuraminidase. The primary defence against H7N9 influenza virus outbreaks is vaccination. For the H7N9 influenza virus, there are presently deactivated and synthetic vaccines available that aim to elicit a defence response towards the pathogen (Wang et al., 2020). Inactivated vaccinations are often given via infusion and are created from deactivated viral fragments. On the other hand, recombinant drugs are created by putting the DNA code for the surface of the viral glycoproteins (HA and NA) into a carrier organism, like an infectious agent or bacterium, which is then utilized to manufacture the vaccine. Injections or nasal sprays can be used to give recombinant vaccinations.
The creation of effective immunizations for the H7N9 influenza virus faces several difficulties. The virus’s rapid pace of mutation and change, which can result in the creation of novel strains unaffected by current vaccinations, constitutes one of the critical problems (Malik et al., 2022). Another difficulty is the virus’s generally low antigenicity, which may render it challenging to elicit an effective immune reaction with a vaccine. Various prophylactic steps may be performed to lower the likelihood of H7N9 influenza virus transmission alongside antiviral drugs and immunizations (Swierczynska et al., 2022). These include washing hands frequently, shunning ill people, and using safety gear like masks when in proximity to those who might be contaminated.
Conclusion
In summary, the H7N9 influenza strain, which has a wrapped virus with 11 amino acid sequences and two glycoproteins, is to blame for several epidemics in China. The strain’s primary targets are the respiratory systems of birds, vertebrates, and humans. Swans are believed to be the primary source of human H7N9 viruses, which can cause respiratory issues and even death in humans. The influenza virus might also produce signs like cough, breathing problems, fever, and even sore throat.
In the most severe situations, the infection may cause acute respiratory problems, septic shock, and failure of several organs. Improvements in bird breeding hygiene requirements and better surveillance for H7N9 contamination in both native and imported birds are required to stop the propagation of the virus. It is crucial to educate people about the dangers of managing fresh birds.
Although there are vaccinations for birds, they are not as successful as those for humans, who can treat H7N9 illnesses with antiviral drugs. However, prompt care and identification are necessary for these medications to be successful. The virus grows, reproduces, and undergoes pathogenesis using exterior glycoproteins, RNA polymerase, and immune evasion.
References
Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., & Zhang, L. (2020). Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet, 395(10223), 507–513. Web.
Chen, Y., Bai, T., & Shu, Y. (2022). Poultry to human passport: cross-species transmission of zoonotic H7N9 avian influenza virus to humans. Zoonoses. Web.
Gržinić, G., Piotrowicz-Cieślak, A., Klimkowicz-Pawlas, A., Górny, R. L., Ławniczek-Wałczyk, A., Piechowicz, L., & Wolska, L. (2023). Intensive poultry farming: A review of the impact on the environment and human health. Science of The Total Environment, 858, 160014. Web.
Guinat, C., Tang, H., Yang, Q., Valenzuela Agüí, C., Vaughan, T. G., Scire, J.,… & Stadler, T. (2023). Bayesian phylodynamics reveals the transmission dynamics of avian influenza A (H7N9) virus at the human–live bird market interface in China. Proceedings of the National Academy of Sciences, 120(17), e2215610120. Web.
Li, Y. T., Linster, M., Mendenhall, I. H., Su, Y. C., & Smith, G. J. (2019). Avian influenza viruses in humans: lessons from past outbreaks. British Medical Bulletin, 132(1), 81-95. Web.
Malik, J. A., Ahmed, S., Mir, A., Shinde, M., Bender, O., Alshammari, F., & Anwar, S. (2022). The SARS-CoV-2 mutation versus vaccine effectiveness: new opportunities to new challenges. Journal of Infection and public health. Web.
Mandary, M. B., Masomian, M., & Poh, C. L. (2019). Impact of RNA virus evolution on quasispecies formation and virulence. International journal of molecular sciences, 20(18), 4657. Web.
Rimi, N. A., Hassan, M. Z., Chowdhury, S., Rahman, M., Sultana, R., Biswas, P. K., & Ross, A. G. (2019). A decade of avian influenza in Bangladesh: Where are we now?Tropical medicine and infectious disease, 4(3), 119. Web.
Toots, M., & Plemper, R. K. (2020). Next-generation direct-acting influenza therapeutics. Translational Research, 220, 33-42. Web.